Roche Holding AGROP
Mentioned
Impact on stocks 1
Health Care▲ · 1 stocks
Roche Holding AGTheme Impact 1
Off-coverage companies 1
Life BiosciencesPrivate▲ Positive
Capitalrelevance
Appointment of a seasoned CFO with financing and M&A experience to the board is positive for the company.
Related news
▲
Genflow trial hits endpoint; 80 Mile agrees takeover
Genflow Biosciences announced that its SLAB gene therapy trial in ageing dogs has met its primary endpoint, and it is now in talks with major animal health companies about a licensing deal. EnergyPathways has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea, moving toward a key Ofgem funding submission. Itaconix is targeting a doubling of revenue to $30 million in the medium term, after half-year revenue jumped 72% on strong detergent demand. Gaming Realms says it is well placed to keep growing despite a UK tax hike hitting margins, with core content licensing revenue up 12% in the first half. Total Graphite reports that fresh drilling in Madagascar has strengthened the case for restarting mining at Vatomina, with one hole returning 19 metres at 3.3% graphite. 80 Mile has agreed indicative terms for a £61.5 million all-share takeover by Nasdaq-listed Greenland Energy, representing a near-47% premium to its share price.
Insilico Medicine Launches Virtual Aging Cell Platform
Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.
▲
Ollin, Beeline, New Limit raise large rounds amid cautious biotech market
Several biotechs have landed sizable funding rounds even as investors remain selective. Ollin Biosciences announced a $330 million series B round co-led by TCGX and Arch Venture Partners to advance its next-generation VEGF/Ang2 bispecific antibody OLN324 for diabetic macular edema and wet age-related macular degeneration. Beeline Medicines, a Bristol Myers Squibb spinout backed by Bain Capital, emerged from stealth with $300 million to develop five in-licensed immunology drugs, including the phase 2 lupus pill afimetoran. New Limit closed a $435 million series C round backed by Founders Fund and Lilly Ventures, reaching an estimated $3.1 billion valuation, and plans to begin clinical trials next year for its epigenetic reprogramming therapy targeting liver aging.